MNOV

MediciNova is a development-stage biopharma with no approved products and effectively no commercial revenue: FY2025 'revenue' was just $410K (down 59% YoY), against a $12.0M net loss and a -$13.3M operating loss. The headline P/S of 157x and -2,929% net margin are not meaningful here — this is not a business being valued on sales but a portfolio of unproven drug candidates (MN-166/ibudilast for progressive MS, ALS, glioblastoma, ARDS; MN-001/tipelukast for NAFLD). The MD&A is explicit about the model: management 'expect[s] to incur substantial net losses for the next several years,' inception-to-date accumulated deficit is $438.7M, and the stated path to value is completing 'proof-of-concept Phase 2 clinical trials' and then seeking strategic alliances or partners — i.e., the outcome hinges on clinical readouts and deals that the provided data cannot let us handicap.

The one genuine positive is balance-sheet quality, not the income statement. Liabilities are tiny ($4.02M) against $41.6M of equity (liabilities/equity 0.10x), and the company holds $30.8M of cash with no meaningful debt on the current balance sheet (the $9.48M long-term and $4.95M current debt figures are stale FY2010 line items, not the present capital structure). Operating cash burn of -$9.81M implies roughly three years of runway at the current pace — enough to reach some catalysts without imminent insolvency, but cash, equity and total assets are all shrinking double digits YoY (cash -23.7%, equity -20.8%), and the MD&A flags that the company 'may seek to raise additional capital,' a standing dilution risk for a 49.2M-share float trading at $1.31.